Allergen Immunotherapy (AIT): a prototype of Precision Medicine

World Allergy Organization Journal

J. Bousquet⁸  O. De Beaumont⁶  M. Wickman²  E. Valovirta³  D. Ryan¹  P. Hellings⁴  C. Bachert⁷  GW Canonica⁵ 

[1] Allergy and Respiratory Research Group, Centre for Population Health Sciences, University of Edinburgh, Edinburgh EH8 9AG, UK;Department of Environmental Medecine, Karolinska Institutet, Sachs’ Children’s Hospital, Stockholm, Sweden;Department of Pulmonary and Allergic Diseases and Clinical Allergology, University of Turku, Turku, Finland;Department of Otorhinolaryngology, University of Amsterdam, Amsterdam, The Netherlands;Allergy and Respiratory Diseases -DIMI Department of Internal Medicine, University of Genova, IRCCS AOU San Martino, Genova 16132, Italy;Stallergenes, Antony, France;Upper Airways Research Laboratory, ENT-Department, University of Ghent, Ghent, 9000, Belgium;University hospital, Montpellier, MACVIA-LR, Contre les Maladies Chronique spour un Vieillissement Actif en Languedoc Roussilon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France

关键词: Allergy;    Personalized medicine;    Precision medicine;    AIT;    Allergen immunotherapy;   

Others  :  1234608
DOI  :  10.1186/s40413-015-0079-7

 received in 2015-06-23, accepted in 2015-08-23,  发布年份 2015

【 摘 要 】

Precision medicine is a medical model aiming to deliver customised healthcare - with medical decisions, practices, and/or products tailored to the individual patient informed but not directed by guidelines. Allergen immunotherapy has unique immunological rationale, since the approach is tailored to the specific IgE spectrum of an individual and modifies the natural course of the disease as it has a persistent efficacy after completion of treatment. In this perspective Allergen Immunotherapy - AIT has to be presently considered a prototype of Precision Medicine.

Precise information and biomarkers provided by systems medicine and network medicine will address the discovery of Allergen immunotherapy biomarkers for (i) identification of the causes, (ii) stratification of eligible patients for AIT and (iii) the assessment of AIT efficacy.

This area of medical technology is evolving rapidly and, compelemented by e-health, will change the way we practice medicine. It will help to monitor patients’ disease control and data for (i) patient stratification, (ii) clinical trials, (iii) monitoring the efficacy and safety of targeted therapies which are critical for reaching an appropriate reimbursement. Biomarkers associated with e-health combined with a clinical decision support system (CDSS) will change the scope of Allergen immunotherapy.

The cost/effectiveness of Allergen immunotherapy is a key issue for successful implementation. It should include the long-term benefits in the pharmaco-economic evaluation, since no other allergy treatment has this specific characteristic.

AIT is the prototype of current and future precision medicine.

【 授权许可】

   
2015 Canonica et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Paving the way for personalizdd medicine, FDA’s role in a new era of medical product development. http://www.fdagov/downloads/ScienceResearch/SpecialTopics/PersonalizedMedicine/UCM372421pdf. 2013
• [2]Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010; 363(4):301-4.
• [3]Bousquet J, Jorgensen C, Dauzat M, Cesario A, Camuzat T, Bourret R et al.. Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies. Curr Pharm Des. 2014; 20(38):5928-44.
• [4]Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P et al.. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365(18):1663-72.
• [5]Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015; 372(9):793-5.
• [6]Braido F, Holgate S, Canonica GW. From "blockbusters" to "biosimilars": an opportunity for patients, medical specialists and health care providers. Pulm Pharmacol Ther. 2012; 25(6):483-6.
• [7]Vieths S, Bieber T. Personalised medicine for the diagnosis and treatment of allergic diseases. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2013; 56(11):1531-7.
• [8]Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A et al.. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J. 2014; 44(2):304-23.
• [9]Bousquet J, Bourquin C, Augé P, Domy P, Bringer J, Camuzat T et al.. MACVIA-LR Reference Site of the European Innovation Partnership on Active and Healthy Ageing. Eur Geriatr Med. 2014; 5(6):406-15.
• [10]Bousquet PJ, Burbach G, Heinzerling LM, Edenharter G, Bachert C, Bindslev-Jensen C et al.. GA2LEN skin test study III: minimum battery of test inhalent allergens needed in epidemiological studies in patients. Allergy. 2009; 64(11):1656-62.
• [11]Canonica GW, Ansotegui IJ, Pawankar R, Schmid-Grendelmeier P, van Hage M, Baena-Cagnani CE et al.. A WAO - ARIA - GA(2)LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J. 2013; 6(1):17.
• [12]Incorvaia C, Mauro M, Ridolo E, Makri E, Montagni M, Ciprandi G. A Pitfall to Avoid When Using an Allergen Microarray: The Incidental Detection of IgE to Unexpected Allergens. J Allergy Clin Immunol Pract. 2014.
• [13]Barber D, Diaz-Perales A, Villalba M, Chivato T. Challenges for allergy diagnosis in regions with complex pollen exposures. Curr Allergy Asthma Rep. 2015; 15(2):496.
• [14]Stringari G, Tripodi S, Caffarelli C, Dondi A, Asero R, Di Rienzo Businco A et al.. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. J Allergy Clin Immunol. 2014; 134(1):75-81.
• [15]Vallier P, Balland S, Harf R, Valenta R, Deviller P. Identification of profilin as an IgE-binding component in latex from Hevea brasiliensis: clinical implications. Clin Exp Allergy. 1995; 25(4):332-9.
• [16]Holzweber F, Svehla E, Fellner W, Dalik T, Stubler S, Hemmer W et al.. Inhibition of IgE binding to cross-reactive carbohydrate determinants enhances diagnostic selectivity. Allergy. 2013; 68(10):1269-77.
• [17]Lupinek C, Wollmann E, Baar A, Banerjee S, Breiteneder H, Broecker BM et al.. Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip. Methods. 2014; 66(1):106-19.
• [18]Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol. 2003; 132(1):13-24.
• [19]Matsuoka T, Shamji MH, Durham SR. Allergen immunotherapy and tolerance. Allergol Int. 2013; 62(4):403-13.
• [20]Akdis CA, Akdis M. Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest. 2014; 124(11):4678-80.
• [21]Allam JP, Novak N. Immunological mechanisms of sublingual immunotherapy. Curr Opin Allergy Clin Immunol. 2014; 14(6):564-9.
• [22]Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95.
• [23]Taylor DR, Pavord ID. Biomarkers in the assessment and management of airways diseases. Postgrad Med J. 2008; 84(998):628-34.
• [24]Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010; 363(2):166-76.
• [25]Fitzpatrick AM, Higgins M, Holguin F, Brown LA, Teague WG. The molecular phenotype of severe asthma in children. J Allergy Clin Immunol. 2010; 125(4):851-7.
• [26]Brasier AR, Victor S, Boetticher G, Ju H, Lee C, Bleecker ER et al.. Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. J Allergy Clin Immunol. 2008; 121(1):30-7.
• [27]Anto JM, Pinart M, Akdis M, Auffray C, Bachert C, Basagana X et al.. Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: a Mechanisms of the Development of Allergy (MeDALL) seminar. J Allergy Clin Immunol. 2012; 129(4):943-54.
• [28]Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Institutes of Medicines of the National Academies http://www.iomedu/Reports/2010/Evaluation-of-Biomarkers-and-Surrogate-Endpoints-in-Chronic-Diseaseaspx. 2010.
• [29]Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest. 2010; 137(6):1410-6.
• [30]Bousquet J, Anto J, Auffray C, Akdis M, Cambon-Thomsen A, Keil T et al.. MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy. 2011; 66(5):596-604.
• [31]Westman M, Lupinek C, Bousquet J, Andersson N, Pahr S, Baar A et al.. Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence. J Allergy Clin Immunol. 2015; 135(5):1199-1206.e11.
• [32]Willis JC, Lord GM. Immune biomarkers: the promises and pitfalls of personalized medicine. Nat Rev Immunol. 2015; 15(5):323.
• [33]Campbell H, Hotchkiss R, Bradshaw N, Porteous M. Integrated care pathways. BMJ. 1998; 316(7125):133-7.
• [34]Integrated Care Pathways users in Scotland (ICPUS). A workbook for people starting to develop integrated care pathways. http://www.icpus.org.uk2007. Accessed May 2015
• [35]Bousquet J, Michel J, Standberg T, Crooks G, Iakovidis I, Gomez M. The European Innovation Partnership on Active and Healthy Ageing: the European Geriatric Medicine introduces the EIP on AHA Column. Eur Geriatr Med. 2014; 5(6):361-2.
• [36]Bousquet J, Anto JM, Demoly P, Schunemann HJ, Togias A, Akdis M et al.. Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int Arch Allergy Immunol. 2012; 158(3):216-31.
• [37]Bousquet J, Schunemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C et al.. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012; 130(5):1049-62.
• [38]Morais-Almeida M, Pite H, Pereira AM, Todo-Bom A, Nunes C, Bousquet J et al.. Prevalence and classification of rhinitis in the elderly: a nationwide survey in Portugal. Allergy. 2013; 68(9):1150-7.
• [39]Morais-Almeida M, Santos N, Pereira AM, Branco-Ferreira M, Nunes C, Bousquet J et al.. Prevalence and classification of rhinitis in preschool children in Portugal: a nationwide study. Allergy. 2013; 68(10):1278-88.
• [40]Klimek L, Bachert C, Mosges R, Munzel U, Price D, Virchow JC et al.. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015; 36(1):40-7.
• [41]Bousquet J, Bachert C, Canonica GW, Casale TB, Cruz AA, Lockey RJ et al.. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol. 2009; 124(3):428-33.
• [42]Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW et al.. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014; 69(7):854-67.
• [43]Bousquet PJ, Bachert C, Canonica GW, Casale TB, Mullol J, Klossek JM et al.. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol. 2010; 126(3):666-8 e1-5.
• [44]Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: Asthma and Rhinitis. Clin Exp Immunol. 2013; 43(8):881-8.
• [45]Just J, Deslandes-Boutmy E, Amat F, Desseaux K, Nemni A, Bourrat E et al.. Natural history of allergic sensitization in infants with early-onset atopic dermatitis: results from ORCA Study. Pediatri Allergy Immunol. 2014; 25(7):668-73.
• [46]Just J, Saint-Pierre P, Gouvis-Echraghi R, Laoudi Y, Roufai L, Momas I et al.. Childhood allergic asthma is not a single phenotype. J Pediatr. 2014; 164(4):815-20.
• [47]Pinart M, Benet M, Annesi-Maesano I, von Berg A, Berdel D, Carlsen KC et al.. Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study. Lancet Respir Med. 2014; 2(2):131-40.
• [48]Hellings PW, Fokkens WJ, Akdis C, Bachert C, Cingi C, Dietz de Loos D et al.. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy. 2013; 68(1):1-7.
• [49]Bousquet PJ, Demoly P, Devillier P, Mesbah K, Bousquet J. Impact of Allergic Rhinitis Symptoms on Quality of Life in Primary Care. Int Arch Allergy Immunol. 2013; 160(4):393-400.
• [50]Sullivan PW, Ghushchyan VH, Slejko JF, Belozeroff V, Globe DR, Lin SL. The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey. J Allergy Clin Immunol. 2011; 127(2):363-9 e1-3.
• [51]Sullivan PW, Slejko JF, Ghushchyan VH, Sucher B, Globe DR, Lin SL et al.. The relationship between asthma, asthma control and economic outcomes in the United States. J Asthma. 2014; 51(7):769-78.
• [52]Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case–control study. J Allergy Clin Immunol. 2007; 120(2):381-7.
• [53]Samolinski B, Fronczak A, Wlodarczyk A, Bousquet J. Council of the European Union conclusions on chronic respiratory diseases in children. Lancet. 2012; 379(9822):e45-6.
• [54]Zuberbier T, Lotvall J, Simoens S, Subramanian SV, Church MK. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy. 2014; 69(10):1275-9.
• [55]Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy. 2004; 59(5):469-78.
• [56]Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK et al.. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006; 368(9537):733-43.
• [57]Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell EA et al.. Worldwide trends in the prevalence of asthma symptoms: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007; 62(9):758-66.
• [58]Bousquet J, Khaltaev N. Global surveillance, prevention and control of Chronic Respiratory Diseases. A comprehensive approach. Global Alliance against Chronic Respiratory Diseases. World Health Organization. 2007:148. ISBN 978 92 4 156346 8.
• [59]Gibson G, Loddenkemper R, Lundback B, Sibille Y. The new European Lung White Book: Respiratory health and disease in Europe: Geneve. ERS Publications; 2013.
• [60]Gibson GJ, Loddenkemper R, Lundback B, Sibille Y. Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J. 2013; 42(3):559-63.
• [61]Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Immunol. 2014; 14(4):363-70.
• [62]Creticos PS, Reed CE, Norman PS, Khoury J, Adkinson NF, Buncher CR et al.. Ragweed immunotherapy in adult asthma. N Engl J Med. 1996; 334(8):501-6.
• [63]Bousquet J, Schunemann HJ, Bousquet PJ, Bachert C, Canonica GW, Casale TB et al.. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy. 2011; 66(6):765-74.
• [64]Dranitsaris G, Ellis AK. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost. J Eval Clin Pract. 2014; 20(3):225-38.
• [65]Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C et al.. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013; 17(27):vi.
• [66]Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011; 12(1):56-68.
• [67]Szepfalusi Z, Bannert C, Ronceray L, Mayer E, Hassler M, Wissmann E et al.. Preventive sublingual immunotherapy in preschool children: First evidence for safety and pro-tolerogenic effects. Pediatr Allergy Immunol. 2014; 25(8):788-95.
• [68]Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med. 2000; 162(4 Pt 1):1391-6.